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Strengths and limitations of this study
 ► This research is an evaluation of a systematically 
developed complex intervention.
 ► The trial is a randomised controlled design with 
broad inclusion criteria to maximise generalisability.
 ► Economic evaluation will determine the cost-effec-
tiveness of the intervention.
 ► Due to the pragmatic nature of this trial only limited 
blinding of the research team to treatment allocation 
is possible.
 ► Exclusion of nursing home residents will restrict the 
relevance of the findings for this subgroup of stroke 
survivors.
AbStrACt
Introduction Survival after stroke is improving, leading 
to increased demand on primary care and community 
services to meet the long-term care needs of people living 
with stroke. No formal primary care-based holistic model 
of care with clinical trial evidence exists to support stroke 
survivors living in the community, and stroke survivors 
report that many of their needs are not being met. We 
have developed a multifactorial primary care model to 
address these longer term needs. We aim to evaluate 
the clinical and cost-effectiveness of this new model of 
primary care for stroke survivors compared with standard 
care.
Methods and analysis Improving Primary Care After 
Stroke (IPCAS) is a two-arm cluster-randomised controlled 
trial with general practice as the unit of randomisation. 
People on the stroke registers of general practices will 
be invited to participate. One arm will receive the IPCAS 
model of care including a structured review using a 
checklist; a self-management programme; enhanced 
communication pathways between primary care and 
specialist services; and direct point of contact for 
patients. The other arm will receive usual care. We aim 
to recruit 920 people with stroke registered with 46 
general practices. The primary endpoint is two subscales 
(emotion and handicap) of the Stroke Impact Scale (SIS) as 
coprimary outcomes at 12 months (adjusted for baseline). 
Secondary outcomes include: SIS Short Form, EuroQol EQ-
5D-5L, ICEpop CAPability measure for Adults, Southampton 
Stroke Self-management Questionnaire, Health Literacy 
Questionnaire and medication use. Cost-effectiveness 
of the new model will be determined in a within-trial 
economic evaluation.
Ethics and dissemination Favourable ethical opinion was 
gained from Yorkshire and the Humber-Bradford Leeds 
NHS Research Ethics Committee. Approval to start was 
given by the Health Research Authority prior to recruitment 
of participants at any NHS site. Data will be presented at 
national and international conferences and published in 
peer-reviewed journals. Patient and public involvement 
helped develop the dissemination plan.
trial registration number NCT03353519
bACkground And rAtIonAlE
Survival after stroke is improving1 2 leading to 
increased demand on primary care services 
to meet the long-term care needs of people 
with stroke living in the community. Surveys 
suggest these needs are not being adequately 
addressed and that many stroke survivors 
are dissatisfied with care after discharge 
from hospital.3 4 Approximately a third of 
stroke survivors have moderate to severe 
levels of disability at 6 months.5 In addition 
to the many physical consequences of stroke, 
commonly reported areas of concern include 
information needs, feelings of abandonment, 
problems with communication,3 emotional, 
psychological and social problems, fatigue, 
and cognitive sequelae including poor 
memory and concentration.6
Little evidence exists as to how best to 
support long-term stroke survivors7 especially 
beyond the first year after stroke,8 and recent 
trials of greater specialist input after discharge 
from hospital have had mixed results.7 9 No 
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care with clinical trial evidence exists to support stroke 
survivors living in the community, and stroke survi-
vors report that many of their needs are not being met. 
Systematic reviews have demonstrated that self-manage-
ment after stroke shows promise, but evidence on aspects 
such as mood and social tasks remains sparse, with wide 
CIs around effects on outcomes such as quality of life.10–12
Primary care could play an important role in the care of 
people with stroke, including secondary prevention and 
risk factor management, supporting access to community 
services, facilitating transfer back to specialist services, 
and education and provision of information about 
stroke. However, the feeling of ‘abandonment’ of people 
with stroke after hospital discharge suggests this role is 
not being fulfilled. Indeed, current recommendations,13 
such as for a structured review of needs beyond the first 
6 weeks after discharge, are not being implemented.14
We have developed a novel multifactorial primary care 
model to address the longer term needs of stroke survi-
vors living in the community. The components of the 
model have been assessed for feasibility of delivery within 
primary care across four general practices prior to starting 
the Improving Primary Care After Stroke (IPCAS) trial. 
This led to several minor procedural amendments aimed 
at improving implementation of the intervention.
AIMS
The IPCAS trial aims to evaluate the clinical and cost-ef-
fectiveness of a new model of primary care for stroke 
survivors living in the community compared with stan-
dard care.
The primary endpoint for the trial will be two subscales 
(emotion and handicap) of the Stroke Impact Scale (SIS 
v3.0)15 as coprimary outcomes at 12 months (adjusted for 
baseline).
trial design
Two-arm cluster-randomised controlled trial with general 
practice as the unit of randomisation.
Randomisation will be performed as random permuted 
block randomisation with a 1:1 allocation stratified by 
practice size.
Setting and participants
General practices with a stroke register comprising a 
minimum of 100 patients and representing a range of 
urban/rural and different socioeconomic status from the 
East of England and the East Midlands will be recruited. 
We aim to recruit approximately 920 people with a 
confirmed history of stroke registered with 46 general 
practices. Given that primary care addresses the long-
term needs of stroke survivors we did not restrict partici-
pants to any specific time interval after their stroke.
Inclusion criteria
 ► On practice register with a history of stroke.
 ► Able to provide written informed consent (with or 
without the help of a carer).
 ► Age 18 years or older.
Exclusion criteria
 ► Patients on the palliative care register.
 ► Living in a nursing home.
MEthodS
recruitment of stroke survivors
Prior to practice-level randomisation (see below) elec-
tronic searches of the clinical computer system will 
generate a list of people with a history of stroke who meet 
the inclusion criteria for the study.
Potentially eligible participants will be sent an invi-
tation by their general practitioner (GP) to take part 
in the study. If practices had 110 or fewer such people, 
invitations were sent to all those eligible. For larger 
practices, a random sample of 110 eligible patients were 
sent invitations. The invitation pack contains an invita-
tion cover letter, the Patient Information Sheet, consent 
form (online supplementary appendix 1), a question-
naire containing the coprimary outcomes and instruc-
tions to return the consent form and questionnaire to 
the researchers in a prepaid envelope (provided). If 
no response is received within 2 weeks from the initial 
mail-out, the practice will send a reminder. If no response 
is received after the reminder then no further attempts at 
contact will be made.
randomisation
Once all invitation letters and reminders have been 
sent out to patients within a practice, the practice will 
be randomised to intervention or control (ratio of 1:1). 
Randomisation will be performed centrally by the trial 
statistician using a stratified, random permuted block 
design. The stratification factor will be GP practice size, 
split into two levels: ≤10 500 and >10 500 patients, which 
reflects the median GP list size in the catchment area. 
The IPCAS trial flow chart can be seen in figure 1.
Intervention
The new model of care incorporates a multifaceted 
package of service aimed at providing a structured review 
of stroke care needs, a self-management programme for 
survivors and their carers, optimised communication 
between patients and healthcare services, enhanced 
communication pathways between the different care 
services and increased awareness of and access to national 
and local community and charity-provided services. A 
logic model depicting the rationale for the IPCAS trial 
intervention can be seen in figure 2.
Structured review of patient needs
A structured review will be performed by a practice nurse 
or other appropriately trained member of the practice 
team. Consenting patients will be invited for review by 
the practice in the same way that they would normally 
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Figure 1 IPCAS trial flow chart. GP, general practice; 
IPCAS, Improving Primary Care After Stroke; MLAS, My Life 
After Stroke.
Figure 2 Logic model for the IPCAS trial intervention. GP, general practitioner; HCP, healthcare practitioner; IPCAS, Improving 
Primary Care After Stroke; SSSQ, Southampton Stroke Self-management Questionnaire.
service). Where practicable, this review will be incorpo-
rated into the regular annual review recommended by 
current guidelines.13 A 15-item checklist of common post-
stroke needs16 adapted from a checklist recommended 
by the World Stroke Organisation (WSO)17 will be sent 
to the stroke survivor in advance, who will be asked to 
tick all needs which apply to them, and to bring this to 
the appointment. At the review, the patient will be asked 
which of the ticked items is their priority for immediate 
attention. Practice staff will discuss and address up to 
three key needs prioritised by the patient.
The review will last approximately 20–30 min and may 
include a routine physical check-up (eg, blood pressure, 
record of immunisation and medication review dependent 
on normal clinical practice at the GP surgery) followed 
by the discussion of poststroke care needs as identified 
by the stroke survivor. The outcome of the review will be 
an action plan agreed with the stroke survivor on how to 
address each of the key needs identified in the review.
The patient will be provided with an information leaflet 
introducing the self-management programme, with 
instructions on how to get further information and how 
to access the programme.
Self-management programme (My Life After Stroke)
‘My Life After Stroke’ (MLAS) is a theory-driven self-man-
agement education programme with an explicit phil-
osophical underpinning for stroke survivors and their 
carers (where appropriate) consisting of an initial indi-
vidual preparatory session, four weekly group-based 
sessions and a final individual session. Individual appoint-
ments last approximately 30–45 min. Group sessions will 
include stroke survivors and their carers (where relevant) 
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Group sessions cover a variety of topics including 
risk factors for stroke and prevention, psychological 
well-being, information, social needs, problem solving 
and goal setting. Participants will be given a handbook 
containing educational content and further information 
based on the session topics.
The programme will be run by two trained facilitators 
(healthcare professionals or people working in the volun-
tary sector) with an interest in or experience of stroke. All 
sessions will be held at a suitable, accessible, local commu-
nity facility.
Direct point of contact
A direct point of contact at the GP practice will be 
provided for stroke survivors and their carers. The staff 
member conducting the enhanced annual review will 
explain how to access the direct point of contact. Survi-
vors or carers will be able to call the practice and indicate 
that they would like to talk to someone about a stroke-re-
lated problem. A single or several practice nurses or other 
appropriately trained healthcare members of the practice 
team will assume the role. If none of these people are 
available at the time of the call, a designated member 
of the care team will phone back. The aim of the direct 
point of contact will be to provide support and advice 
for stroke-specific issues, arranging follow-up appoint-
ments and signposting to further specialist or community 
services.
Enhanced communication pathways
We will arrange a meeting between primary care staff from 
several practices and specialist staff (hospital and commu-
nity) to facilitate primary/secondary care communication 
going forward. All practice staff involved with the care of 
stroke survivors will be encouraged to attend additional 
training/meetings organised by the specialist services, 
and given direct contact details for informal communi-
cation. Video recordings of local specialist(s) describing 
their service, the type of patients normally referred to the 
service and ways of contacting the service will be made 
available to all general practice staff.
Service mapping
To support the information needs regarding local 
services for stroke-related problems, the care team will be 
provided with a catalogue of stroke (and other relevant) 
services in participating localities, including information 
on how to access them. This resource will be available in 
several electronic and hard copy formats to enable easy 
access by staff at the practice.
Training for general practice staff
Training for practice staff involved in structured stroke 
reviews will include an overview of stroke and stroke-re-
lated long-term needs, followed by discussion of vignettes 
based on items from the stroke review checklist. Practice 
staff will suggest and discuss with the research team the 
most suitable course of action in each situation tailored 
to local context.
The list of key health and social services available in 
the local area will be provided, and practice staff will be 
familiarised with the service mapping resource that will 
be made available to them at the practice. The outcomes 
of the structured review will be recorded on a template 
in the patient records. We will discuss with the practice 
how best to embed the direct point of contact role within 
the current practice operations. To enable ease of atten-
dance the training will be held in the practice and will last 
approximately 2 hours.
Control arm
General practices randomised to the control arm of the 
trial will continue to deliver usual stroke care. Currently 
no standard package of long-term care for stroke survi-
vors exists in primary care, and therefore we expect ‘usual 
care’ to vary between practices. We will capture informa-
tion on the key elements of care provided by each partic-
ipating practice to enable comparison between the two 
arms of the trial.
Demographic data: age, gender, ethnicity and postcode 
will be collected via postal questionnaire at the time of 
invitation to the study.
Primary outcome
The primary endpoint for the trial will be two subscales 
(emotion and handicap) of the SIS v3.015 as coprimary 
outcomes at 12 months (adjusted for baseline) after 
randomisation of the practice.
Secondary outcomes
To be collected at baseline, 6 and 12 months (*Collected 
at 12 months’ follow-up only):
 ► SIS Short Form.15
 ► EuroQol EQ-5D-5L.18
 ► ICEpop CAPability measure for Adults (ICECAP-A).19
 ► Time since stroke.
 ► * Comorbidity, medication use (prescription and 
‘over the counter’).
 ► * Southampton Stroke Self-management 
Questionnaire.20
 ► * Health Literacy Questionnaire.21
data collection
In this pragmatic, practice-level, cluster-randomised trial 
blinding to treatment allocation of the research team or 
clinical staff involved in delivering the intervention or 
control condition is not possible. The primary outcome 
will be captured by postal questionnaires sent to partici-
pants. Only in the event of missing data from the primary 
outcome will participants be contacted by the research 
team to either encourage them to return their question-
naire or to complete missing items via telephone. Ques-
tionnaire data entry onto an electronic spreadsheet will 
be outsourced to a third-party provider via secure data 
transfer for blinded data entry. The ‘coded-allocation’ 
spreadsheet will then be returned to the trial statistician, 
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Figure 3 Improving Primary Care After Stroke (IPCAS) 
trial Standard Protocol Items: Recommendations for 
Interventional Trials (SPIRIT) flow chart showing scheduled 
enrolment, interventions and assessments of participants.
Baseline: The primary outcome data (emotion and 
handicap subscales of the SIS) will be collected via postal 
questionnaire at the time of invitation to the study prior 
to randomisation of the practice. Secondary outcome 
data (SIS Short Form, EuroQol EQ-5D-5L and ICECAP-A) 
will be collected by postal questionnaire after receipt of 
consent. Non-responders to the secondary outcome ques-
tionnaire will be followed up by telephone or the most 
appropriate method for a participant with aphasia.
Follow-up: At 6 and 12 months by postal questionnaire. 
Non-responders/incomplete responders will be followed 
up by telephone or the most appropriate method for a 
participant with aphasia.
A review of the GP notes of consenting participants will 
be conducted. Data extracted will include number and 
nature of primary care visits, secondary care inpatient 
and outpatient visits, investigations, medications and use 
of social services.
The IPCAS trial Standard Protocol Items: Recom-
mendations for Interventional Trials flow chart showing 
scheduled enrolment, interventions and assessments of 
participants can be seen in figure 3.
Patient involvement
Patient and members of the public were involved at several 
stages of the trial, including the design, management 
and conduct of the trial. We received input from stroke 
survivors in the design of the trial materials and manage-
ment oversight through membership of the trial steering 
committee (TSC). We carefully assessed the burden of 
the trial interventions on patients. We continue to have 
patient involvement with the trial through representation 
on the steering committee and the investigators team. 
We will seek wider patient and public involvement in the 
interpretation of the trial findings and in development of 
an appropriate method of dissemination.
Statistical methods and analysis
Sample size
With 23 clusters per arm and an average of 20 patients 
per cluster, assuming an intraclass correlation of 0.03, a 
typical coefficient of variation of the cluster size of 0.6522 
and 2.5% significance (adjusted to 2.5% because of the 
use of two coprimary outcomes), we would be able to 
detect an effect size of 0.33 with at least 90% power on the 
coprimary outcomes (emotion and handicap subscales 
of the SIS v3.015). The sample size calculation has been 
inflated to allow for a rate of 20% loss to follow-up for 
patients within clusters. Loss to follow-up of entire clus-
ters is not anticipated.
Analysis of primary outcome
We will use intention to treat methods for the analysis of 
the primary endpoints. A mixed effects model will be used 
to model each of the coprimary outcomes with a cluster 
random effect and fixed effects for the intervention and 
covariates that might potentially confound the relation-
ship. Distributional assumptions will be assessed graph-
ically by residual q-q plots and residual by fitted value 
plots. To handle the coprimary outcomes, 97.5% CIs will 
be reported for the two primary treatment effects which 
are equivalent to having the Bonferonni correction on 
the planned 5% significance level for a single endpoint.
Missing data will be analysed under the assumptions of 
missing completely at random and missing at random. 
Multiple imputation will be used to impute missing 
outcome data and the various potential predictors of 
missingness will be included in the imputation model.
Secondary analysis will look at the effect of time since 
stroke on uptake and effectiveness of the intervention.
Economic evaluation
The cost-effectiveness (cost-utility) of the new system of 
care (intervention package) compared with usual care 
will be determined in a within-trial economic evaluation. 
Data will be collected via electronic primary care records 
and patient questionnaires on resource use implications 
of the intervention (including training), primary care 
visits, secondary care inpatient and outpatient visits, inves-
tigations, medications and use of social services. Patient 
and carer-incurred costs will also be considered to allow 
analysis from a broader societal perspective. Data collec-
tion will be undertaken within the trial to determine the 
time taken to deliver the structured review, and any addi-
tional resources required. Attendance at the individual 
and group MLAS sessions will also be recorded for every 
participant, and each session will be costed, taking into 
account staff time, any consumables and use of the venue. 
Standard unit costs will be applied to healthcare resource 
use including National Health Service (NHS) reference 
costs, the British National Formulary for medications and 
Unit Costs for Health and Social Care (Personal Social 
Services Research Unit).
The main outcomes of interest from the trial are quality 
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12 months after entry into the trial) and capability (using 
the ICECAP-A questionnaire).19 Initially, a cost-conse-
quence analysis will be performed, to present a disaggre-
gated analysis of all mean resource use and costs related 
to the intervention and usual care, healthcare, social care, 
patient/carer costs and EQ-5D-5L and ICECAP-A scores 
at all time points. Quality-adjusted life years (QALY) will 
be calculated by the area under the curve method using 
responses at all time points, and adjusted for baseline 
covariates including EQ-5D-5L score. Multiple impu-
tation will be undertaken where there are missing cost 
and outcome data. An incremental cost-utility analysis 
will then be undertaken to determine the cost per QALY 
gained of the intervention compared with usual care.
To explore uncertainties in the analyses, deterministic 
sensitivity analysis is proposed to test the robustness of the 
results when varying key assumptions (eg, length of time 
required to deliver the intervention).
Process evaluation
A process evaluation will examine the implementation 
of the IPCAS trial using both quantitative and qualita-
tive methods. As well as capturing process variables, the 
evaluation will also entail a multidimensional approach 
to assessing intervention fidelity—the extent to which 
an intervention is delivered as planned.23 Using the 
US National Institutes of Health Behaviour Change 
Consortium (NIHBCC) guidance24 we will conduct a 
‘whole picture’ assessment of the intervention across 
five fidelity dimensions: (1) design, (2) training, (3) 
delivery, (4) receipt, and (5) enactment. An overview is 
provided below, with the full protocol reported elsewhere 
(currently in submission).
Fidelity of design will be assessed through mapping 
intervention components to its purported theoretical 
frameworks. All intervention components have been spec-
ified a priori and recorded. Additionally, treatment differ-
entiation (ie, extent to which intervention and control 
group practices differ) is considered by comparing the 
contents of the intervention versus usual care. Fidelity 
of training will be assessed using self-complete question-
naires (MLAS), video-recorded observations (MLAS) and 
audio-recorded observations (IPCAS). Fidelity of delivery 
will be assessed through audio-recorded observations 
(IPCAS), structured telephone calls to healthcare profes-
sionals and direct observations (MLAS). In addition, 
semistructured interviews will be conducted with health-
care professionals delivering the intervention, which will 
help assess both training and delivery. Fidelity of receipt 
and enactment will be assessed using self-complete ques-
tionnaires (MLAS), structured telephone calls and semi-
structured interviews with participants.
Analysis
Quantitative aspects of the process evaluation (eg, 
process variables, coded video-recorded observations, 
self-complete questionnaires) will be synthesised descrip-
tively. This will include what factors predict intervention 
fidelity. Qualitative aspects of the process evaluation (eg, 
semistructured interviews, qualitative data from ques-
tionnaires) will be synthesised using deductive thematic 
analysis, using the specific domains from the NIHBCC 
guidance.
reporting adverse events
We are not anticipating any intervention-related adverse 
events. Nevertheless, in accordance with Good Clinical 
Practice (GCP), each principal investigator is respon-
sible for reporting all non-exempt serious adverse events 
(SAE) to the chief investigator (CI) within 24 hours of 
first notification. The CI is responsible for ensuring 
the assessment of all SAEs for expectedness and relat-
edness is completed and the onward notification of all 
non-exempt SAEs to the sponsor within 24 hours of first 
notification.
trial management
The trial is cosponsored by NHS Cambridgeshire and 
Peterborough Clinical Commissioning Group and the 
University of Cambridge. The study team work with local 
Clinical Research Networks in the East of England and the 
East Midlands to identify and recruit general practices.
Oversight of the trial will fall to an independent 
committee fulfilling the combined roles of TSC and data 
monitoring committee (DMC). They will provide overall 
supervision of the conduct of the trial on behalf of the 
trial sponsor(s) in accordance with National Institute 
for Health Research recommendations.25 26 There are 
no prespecified criteria for electively stopping the trial 
prematurely. In the event that the joint TSC/DMC raise 
concerns over the safety of participants or the scientific 
integrity of the trial, a decision as to whether to continue 
will be discussed and voted on in keeping with the Terms 
of Reference of the committees and with GCP in Research 
guidelines.
data management and storage
Data completed by participants, such as consent forms 
and questionnaires, will be returned to the study team 
via post using prepaid stamped addressed envelopes. All 
relevant data collected at practice sites will be sent to 
the study team by trained and delegated practice staff 
via a secure transfer server. Paper data will be stored in 
locked filing cabinets within a security card-protected 
building at the University of Cambridge. Electronic data 
(including audio recordings) will be stored on a Secure 
Data Hosting Service protected by a dual authentication 
located on a firewall-protected virtual network (virtual 
LAN). Access to study data is restricted to the study 
team by dual authentication and group permissions. 
All investigators and trial site staff involved in this trial 
will comply with the requirements of the General Data 
Protection Regulation (EU) 2016/679 with regard to the 
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